Cargando…

Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19

The new outbreak of coronavirus disease 2019 (COVID-19) has infected and caused the death of millions of people worldwide. Intensive efforts are underway around the world to establish effective treatments. Immunoglobulin from immunized animals or plasma from convalescent patients might constitute a...

Descripción completa

Detalles Bibliográficos
Autores principales: Botosso, Viviane Fongaro, Jorge, Soraia Attie Calil, Astray, Renato Mancini, de Sá Guimarães, Ana Marcia, Mathor, Monica Beatriz, de Carneiro, Patrícia dos Santos, Durigon, Edison Luiz, Covas, Dimas, de Oliveira, Danielle Bruna Leal, das Neves Oliveira, Ricardo, Maria, Durvanei Augusto, Eto, Silas Fernandes, Gallina, Neuza Maria Frazatti, Pidde, Giselle, Squaiella-Baptistão, Carla Cristina, Silva, Dilza Trevisan, Villas-Boas, Isadora Maria, Fernandes, Dayanne Carla, Auada, Aline Vivian Vatti, Banari, Alexandre Campos, de Souza Filho, Antônio Francisco, Bianconi, Camila, de Agostini Utescher, Carla Lilian, Oliveira, Denise Cristina André, Mariano, Douglas Oscar Ceolin, Barbosa, Flávia Ferreira, Rondon, Giuliana, Kapronezai, Josana, da Silva, Juliana Galvão, Goldfeder, Mauricio Barbugiani, Comone, Priscila, Junior, Regis Edgar Castilho, Pereira, Taiana Tainá Silva, Wen, Fan Hui, Tambourgi, Denise V., Chudzinski-Tavassi, Ana Marisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913704/
https://www.ncbi.nlm.nih.gov/pubmed/35273234
http://dx.doi.org/10.1038/s41598-022-07793-1
_version_ 1784667505073061888
author Botosso, Viviane Fongaro
Jorge, Soraia Attie Calil
Astray, Renato Mancini
de Sá Guimarães, Ana Marcia
Mathor, Monica Beatriz
de Carneiro, Patrícia dos Santos
Durigon, Edison Luiz
Covas, Dimas
de Oliveira, Danielle Bruna Leal
das Neves Oliveira, Ricardo
Maria, Durvanei Augusto
Eto, Silas Fernandes
Gallina, Neuza Maria Frazatti
Pidde, Giselle
Squaiella-Baptistão, Carla Cristina
Silva, Dilza Trevisan
Villas-Boas, Isadora Maria
Fernandes, Dayanne Carla
Auada, Aline Vivian Vatti
Banari, Alexandre Campos
de Souza Filho, Antônio Francisco
Bianconi, Camila
de Agostini Utescher, Carla Lilian
Oliveira, Denise Cristina André
Mariano, Douglas Oscar Ceolin
Barbosa, Flávia Ferreira
Rondon, Giuliana
Kapronezai, Josana
da Silva, Juliana Galvão
Goldfeder, Mauricio Barbugiani
Comone, Priscila
Junior, Regis Edgar Castilho
Pereira, Taiana Tainá Silva
Wen, Fan Hui
Tambourgi, Denise V.
Chudzinski-Tavassi, Ana Marisa
author_facet Botosso, Viviane Fongaro
Jorge, Soraia Attie Calil
Astray, Renato Mancini
de Sá Guimarães, Ana Marcia
Mathor, Monica Beatriz
de Carneiro, Patrícia dos Santos
Durigon, Edison Luiz
Covas, Dimas
de Oliveira, Danielle Bruna Leal
das Neves Oliveira, Ricardo
Maria, Durvanei Augusto
Eto, Silas Fernandes
Gallina, Neuza Maria Frazatti
Pidde, Giselle
Squaiella-Baptistão, Carla Cristina
Silva, Dilza Trevisan
Villas-Boas, Isadora Maria
Fernandes, Dayanne Carla
Auada, Aline Vivian Vatti
Banari, Alexandre Campos
de Souza Filho, Antônio Francisco
Bianconi, Camila
de Agostini Utescher, Carla Lilian
Oliveira, Denise Cristina André
Mariano, Douglas Oscar Ceolin
Barbosa, Flávia Ferreira
Rondon, Giuliana
Kapronezai, Josana
da Silva, Juliana Galvão
Goldfeder, Mauricio Barbugiani
Comone, Priscila
Junior, Regis Edgar Castilho
Pereira, Taiana Tainá Silva
Wen, Fan Hui
Tambourgi, Denise V.
Chudzinski-Tavassi, Ana Marisa
author_sort Botosso, Viviane Fongaro
collection PubMed
description The new outbreak of coronavirus disease 2019 (COVID-19) has infected and caused the death of millions of people worldwide. Intensive efforts are underway around the world to establish effective treatments. Immunoglobulin from immunized animals or plasma from convalescent patients might constitute a specific treatment to guarantee the neutralization of the virus in the early stages of infection, especially in patients with risk factors and a high probability of progressing to severe disease. Worldwide, a few clinical trials using anti-SARS-CoV-2 immunoglobulins from horses immunized with the entire spike protein or fragments of it in the treatment of patients with COVID-19 are underway. Here, we describe the development of an anti-SARS-CoV-2 equine F(ab′)(2) immunoglobulin using a newly developed SARS-CoV-2 viral antigen that was purified and inactivated by radiation. Cell-based and preclinical assays showed that the F(ab′)(2) immunoglobulin successfully neutralizes the virus, is safe in animal models, and reduces the severity of the disease in a hamster model of SARS-CoV-2 infection and disease.
format Online
Article
Text
id pubmed-8913704
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89137042022-03-14 Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19 Botosso, Viviane Fongaro Jorge, Soraia Attie Calil Astray, Renato Mancini de Sá Guimarães, Ana Marcia Mathor, Monica Beatriz de Carneiro, Patrícia dos Santos Durigon, Edison Luiz Covas, Dimas de Oliveira, Danielle Bruna Leal das Neves Oliveira, Ricardo Maria, Durvanei Augusto Eto, Silas Fernandes Gallina, Neuza Maria Frazatti Pidde, Giselle Squaiella-Baptistão, Carla Cristina Silva, Dilza Trevisan Villas-Boas, Isadora Maria Fernandes, Dayanne Carla Auada, Aline Vivian Vatti Banari, Alexandre Campos de Souza Filho, Antônio Francisco Bianconi, Camila de Agostini Utescher, Carla Lilian Oliveira, Denise Cristina André Mariano, Douglas Oscar Ceolin Barbosa, Flávia Ferreira Rondon, Giuliana Kapronezai, Josana da Silva, Juliana Galvão Goldfeder, Mauricio Barbugiani Comone, Priscila Junior, Regis Edgar Castilho Pereira, Taiana Tainá Silva Wen, Fan Hui Tambourgi, Denise V. Chudzinski-Tavassi, Ana Marisa Sci Rep Article The new outbreak of coronavirus disease 2019 (COVID-19) has infected and caused the death of millions of people worldwide. Intensive efforts are underway around the world to establish effective treatments. Immunoglobulin from immunized animals or plasma from convalescent patients might constitute a specific treatment to guarantee the neutralization of the virus in the early stages of infection, especially in patients with risk factors and a high probability of progressing to severe disease. Worldwide, a few clinical trials using anti-SARS-CoV-2 immunoglobulins from horses immunized with the entire spike protein or fragments of it in the treatment of patients with COVID-19 are underway. Here, we describe the development of an anti-SARS-CoV-2 equine F(ab′)(2) immunoglobulin using a newly developed SARS-CoV-2 viral antigen that was purified and inactivated by radiation. Cell-based and preclinical assays showed that the F(ab′)(2) immunoglobulin successfully neutralizes the virus, is safe in animal models, and reduces the severity of the disease in a hamster model of SARS-CoV-2 infection and disease. Nature Publishing Group UK 2022-03-10 /pmc/articles/PMC8913704/ /pubmed/35273234 http://dx.doi.org/10.1038/s41598-022-07793-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Botosso, Viviane Fongaro
Jorge, Soraia Attie Calil
Astray, Renato Mancini
de Sá Guimarães, Ana Marcia
Mathor, Monica Beatriz
de Carneiro, Patrícia dos Santos
Durigon, Edison Luiz
Covas, Dimas
de Oliveira, Danielle Bruna Leal
das Neves Oliveira, Ricardo
Maria, Durvanei Augusto
Eto, Silas Fernandes
Gallina, Neuza Maria Frazatti
Pidde, Giselle
Squaiella-Baptistão, Carla Cristina
Silva, Dilza Trevisan
Villas-Boas, Isadora Maria
Fernandes, Dayanne Carla
Auada, Aline Vivian Vatti
Banari, Alexandre Campos
de Souza Filho, Antônio Francisco
Bianconi, Camila
de Agostini Utescher, Carla Lilian
Oliveira, Denise Cristina André
Mariano, Douglas Oscar Ceolin
Barbosa, Flávia Ferreira
Rondon, Giuliana
Kapronezai, Josana
da Silva, Juliana Galvão
Goldfeder, Mauricio Barbugiani
Comone, Priscila
Junior, Regis Edgar Castilho
Pereira, Taiana Tainá Silva
Wen, Fan Hui
Tambourgi, Denise V.
Chudzinski-Tavassi, Ana Marisa
Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19
title Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19
title_full Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19
title_fullStr Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19
title_full_unstemmed Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19
title_short Anti-SARS-CoV-2 equine F (Ab′)(2) immunoglobulin as a possible therapy for COVID-19
title_sort anti-sars-cov-2 equine f (ab′)(2) immunoglobulin as a possible therapy for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913704/
https://www.ncbi.nlm.nih.gov/pubmed/35273234
http://dx.doi.org/10.1038/s41598-022-07793-1
work_keys_str_mv AT botossovivianefongaro antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT jorgesoraiaattiecalil antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT astrayrenatomancini antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT desaguimaraesanamarcia antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT mathormonicabeatriz antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT decarneiropatriciadossantos antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT durigonedisonluiz antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT covasdimas antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT deoliveiradaniellebrunaleal antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT dasnevesoliveiraricardo antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT mariadurvaneiaugusto antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT etosilasfernandes antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT gallinaneuzamariafrazatti antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT piddegiselle antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT squaiellabaptistaocarlacristina antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT silvadilzatrevisan antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT villasboasisadoramaria antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT fernandesdayannecarla antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT auadaalinevivianvatti antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT banarialexandrecampos antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT desouzafilhoantoniofrancisco antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT bianconicamila antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT deagostiniuteschercarlalilian antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT oliveiradenisecristinaandre antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT marianodouglasoscarceolin antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT barbosaflaviaferreira antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT rondongiuliana antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT kapronezaijosana antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT dasilvajulianagalvao antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT goldfedermauriciobarbugiani antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT comonepriscila antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT juniorregisedgarcastilho antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT pereirataianatainasilva antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT wenfanhui antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT tambourgidenisev antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19
AT chudzinskitavassianamarisa antisarscov2equinefab2immunoglobulinasapossibletherapyforcovid19